Premium
Daily Enteral DHA Supplementation Alleviates Deficiency in Premature Infants
Author(s) -
Baack Michelle L.,
Puumala Susan E.,
Messier Stephen E.,
Pritchett Deborah K.,
Harris William S.
Publication year - 2016
Publication title -
lipids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.601
H-Index - 120
eISSN - 1558-9307
pISSN - 0024-4201
DOI - 10.1007/s11745-016-4130-4
Subject(s) - docosahexaenoic acid , medicine , tolerability , gestational age , parenteral nutrition , infant formula , placebo , enteral administration , randomized controlled trial , bronchopulmonary dysplasia , lipidology , necrotizing enterocolitis , polyunsaturated fatty acid , neonatology , pediatrics , gastroenterology , clinical chemistry , fatty acid , pregnancy , biochemistry , adverse effect , biology , genetics , alternative medicine , pathology
Docosahexaenoic acid (DHA) is an essential fatty acid (FA) important for health and neurodevelopment. Premature infants are at risk of DHA deficiency and circulating levels directly correlate with health outcomes. Most supplementation strategies have focused on increasing DHA content in mother's milk or infant formula. However, extremely premature infants may not reach full feedings for weeks and commercially available parenteral lipid emulsions do not contain preformed DHA, so blood levels decline rapidly after birth. Our objective was to develop a DHA supplementation strategy to overcome these barriers. This double‐blind, randomized, controlled trial determined feasibility, tolerability and efficacy of daily enteral DHA supplementation (50 mg/day) in addition to standard nutrition for preterm infants (24–34 weeks gestational age) beginning in the first week of life. Blood FA levels were analyzed at baseline, full feedings and near discharge in DHA ( n = 31) or placebo supplemented ( n = 29) preterm infants. Term peers ( n = 30) were analyzed for comparison. Preterm infants had lower baseline DHA levels ( p < 0.0001). Those receiving DHA had a progressive increase in circulating DHA over time (from 3.33 to 4.09 wt% or 2.88 to 3.55 mol%, p < 0.0001) while placebo‐supplemented infants (receiving standard neonatal nutrition) had no increase over time (from 3.35 to 3.32 wt% or 2.91 to 2.87 mol%). Although levels increased with additional DHA supplementation, preterm infants still had lower blood DHA levels than term peers (4.97 wt% or 4.31 mol%) at discharge ( p = 0.0002). No differences in adverse events were observed between the groups. Overall, daily enteral DHA supplementation is feasible and alleviates deficiency in premature infants.